Loading clinical trials...

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients | Clinical Trials | Clareo Health

RECRUITINGNA

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Phase II/III Randomized Clinical Trial of Radiosensitivity-Assisted Personalized Adaptive RadioTherapy (RAPART) in Locally Advanced Non-small Cell Lung Cancer Patients

NCT07164885•Capital Medical University

View on ClinicalTrials.gov

Summary

This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult research participants, aged over 18 years old;
•Non small cell lung cancer that requires pathological confirmation;
•All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);
•ECOG physical condition is 0-2;
•In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment.

Exclusion Criteria

•Prisoners who are not convenient for close clinical follow-up;
•Study participants with contraindications to radiation therapy.

Locations (1)

University of Hong Kong Shenzhen Hospital

Shenzhen, Guangdong, China

Key Dates

Start Date

February 17, 2025

Primary Completion Date

December 30, 2027

Completion Date

December 30, 2027

Last Updated

December 2, 2025

Enrollment

911

ESTIMATED participants

Conditions

Locally Advanced Non-small Cell Lung Cancer

Interventions

Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）

RADIATION

Conventional radiotherapy

RADIATION

Contacts

Feng-Ming (Spring) Kong

CONTACT

+86 188 0755 0703 kong0001@hku.hk

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

NCT06755684

EGFRNon-Small Cell Lung Cancer+6 more

View study

UNKNOWN

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

NCT06287320

Locally Advanced Non-small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Inclusion Criteria

Exclusion Criteria

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy